Various coding and non-coding transcripts are known to associate with chromatin and now there is accumulating evidence that interaction between RNA-binding proteins (RBPs) and RNA molecules regulate not only co-transcriptional mRNA processing, but also other biological processes within the nucleus. Although over a thousand of RBPs have been identified by several mass spectrometry-based methods, it is still unclear which of these RBPs actually associate with chromatin, especially through interaction with RNAs. In addition, biological outcomes of such RBP-RNA-chromatin interactions are yet to be elucidated.
Introduction
Since the discovery of a large collection of mammalian non-coding RNAs in mid-2000, intense research has been carried out around the world to unravel the physical and functional properties of these non-coding transcripts 1, 2 . In recent years, it has become apparent that many long non-coding RNAs (lncRNAs) are localized in the nucleus and a pool of chromatin-associated RNAs (caRNAs) have been identified 3, 4 . Chromatin act as a platform for many biological processes. The most active event taking place on chromatin is transcription and it was found that a large proportion of caRNAs are products of ongoing transcription 4, 5 . These transcripts can recruit factors involved in co-transcriptional processing like splicing of pre-mRNA. More intriguingly, transcription of coding and non-coding transcripts from a specific locus or chromosomal region can, in some cases, recruit chromatin modifiers and/or chromatin binding proteins to mediate epigenetic regulation of gene activity 2, 6, 7 . Furthermore, a chromatin-associated lncRNA has been shown to interact with a nuclear matrix protein to induce clustering of individual gene loci in trans 8 . However, since information on a functional interaction between a particular caRNA and a certain RNA binding protein (RBP) are rather scarce and fragmentary, it is still difficult to generalize and categorize different types of caRNA -RBP interactions and link them to a repertoire of chromatin-based biological processes.
In parallel to the 'RNA-centric' studies, development of crosslinking and immunoprecipitation (CLIP)-mass spectrometry (MS) and similar methodologies greatly accelerated identification of RNA-binding proteins (RPBs) [9] [10] [11] [12] [13] . At the present time, over 1,000 proteins have been identified as RBP candidates in mouse and human cultured cells 14 . Conrad et al. addressed nuclear localization or enrichment of these RBPs and identified sets of nuclear RBPs and chromatin-associated RBPs (caRBPs) 9, 12 . However, the use of oligo-dT pulldown in the study is expected to have introduced a bias towards identification of RBPs interacting with polyA+ RNAs and may have excluded RBPs associating preferentially to polyA-RNAs, including many nascent transcripts that are the major In order to establish a simple and reliable method to systematically identify caRBPs, especially whose association with chromatin is RNA-dependent, we adopted and modified the method to isolate caRNAs for proteomic study 4, 9 . Using HeLa S3 cells, we performed cell fractionation to enrich chromatin and insoluble nuclear substructures. This was followed by RNase A treatment of the chromatin/insoluble fraction to release proteins that are anchored or bridged to chromatin via RNA, and the RNase A-solubilized proteins were analyzed by mass spectrometry. As a result, we identified 156 proteins that were released from chromatin/insoluble nuclear structures by RNase A treatment.
The majority of the identified caRBP candidates were already known RBPs or RBP candidates. This method is highly applicable to different types of cells or organisms, thus potentially enables us to examine and explore caRNA-caRPB interactions in different biological contexts.
Materials and Methods

Cell culture
HeLa S3 cells were grown in high-glucose DMEM (Nacalai tesque), 10% FBS (Gibco), 1x
Penicillin-Streptomycin (Nacalai tesque). To inhibit transcriptional elongation, the cells were treated with 100 µM 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole (DRB) (Sigma Aldrich) for 2 or 4 h.
Cell Fractionation and RNase A treatment
Cell fractionation was carried out essentially as described by Werner et al. 4 . In brief, 0. NP-40, 10 mM MgCl 2 , 1 mM DTT) was subsequently added, incubated for 5 min on ice and centrifuged at 1,200 x g for 5 min at 4 ºC. The supernatant was recovered as 'nucleoplasmic fraction'.
The insoluble pellet was washed twice with 1 ml of Buffer A as described above. The washed pellet was resuspended in 250 µl of Buffer A and 100 µl-aliquots were transferred into two 1.5 ml tubes.
One aliquot was treated with 5 µg RNase A (10 mg/ml, DNase-free, Nacalai tesque) for 30 min at room temperature. Another aliquot was kept as RNase A-untreated control. After the incubation, the samples were centrifuged at 1,200 x g for 5 min at 4 ºC, and the supernatant was collected as 'RNase A-soluble' fraction. The pellet was washed once with 1 ml of Buffer A and resuspended in 0.5 ml of Buffer A. To all fractions, 6x SDS sample buffer was added to the final concentration of 1x. The samples were boiled for 5 min at 95 ºC, resolved on a 4 -20% gradient SDS polyacrylamide gel (Cosmobio) and stained with rapid stain CBB kit (Nacalai tesque, for general checks) or GelCode
Blue Safe Protein Stain (Thermo Fisher Scientific, for mass spectrometry).
Mass spectrometry and data analysis
For the in-gel digestion of proteins, each lane was excised 13-16 gel slices, and then these gel slices 
Western blotting
Samples were resolved on a 5 -20% gradient SDS polyacrylamide gels (Nacalai tesque). The separated proteins were blotted onto PVDF membrane for 1 ~1.5 h at 100 V. The membranes were blocked with 5% skim milk in TBS-T (50 mM Tris-HCl [pH7.6], 150 mM NaCl, 0.05% Tween 20) for 30 min on a rocking platform and then, incubated with primary antibodies (diluted with 2% skim milk in TBS-T) for 2 h at room temperature. The membranes were washed with TBS-T three times (5 min each round on a rocking platform, at room temperature). The washed membranes were incubated with secondary antibodies (diluted in 5% skim milk in TBS-T) for 1 h at room temperature. The membranes were then washed with TBS-T three times (8 ~ 10 min each round on a rocking platform, at room temperature). Signals from the antibodies were detected using ECL (GE Healthcare) or ECL plus reagent (Thermo scientific pierce) and images were captured with LAS-3000 mini (Fuji film).
The antibodies used in this study are listed in supplementary table S1.9.
Results and Discussion
Enrichment of proteins bound tightly to chromatin
In order to enrich chromatin and other insoluble nuclear substructures including nuclear envelop and nuclear scaffold/matrices, HeLa S3 cells were fractionated into 'cytoplasmic', 'nucleoplasmic' and 'chromatin/insoluble' fractions using the method describe to enrich caRNAs 4 ( Figure 1A ). Cells were first lysed in hypotonic buffer containing a non-ionic detergent, Triton X-100, and then, isolated nuclei were lysed in a buffer containing a near physiological concentration (ca. 180 mM) of monovalent salt and a moderate concentration (0.5 M) of urea. The addition of urea to the buffer is thought to effectively reduce RNAs and proteins weakly or non-specifically bound to chromatin 4, 15 . As shown in Figure 1B , CBB-staining patterns of each fraction were quite distinct from each other ( Figure 1B , lanes 2-4 'cytoplasmic'; lanes 6-8 'nucleoplasmic'; lanes 10-12 'chromatin').
According to western blot analysis of each fraction, typical controls for cytoplasmic and nuclear fractions were enriched in expected fractions; α-tubulin was enriched in cytoplasmic fraction whereas Lamin B and histone H3 were enriched in chromatin/insoluble fractions ( Figure 1C ). Other nuclear proteins (TIF1β, HP1β, hnRNP U, Ku80) showed less clear-cut distribution patterns and some of these factors were more enriched in cytoplasmic and nucleoplasmic fractions than in chromatin fraction ( Figure 1C ). It is likely that Triton X-100 in the hypotonic buffer permeabilized nuclei and this led to release of loosely chromatin-bound and/or abundant nuclear proteins in the 'cytoplasmic' fraction.
Further treatment with a salt and urea seems to have enhanced release of nuclear proteins associated with nuclear substructures. In summary, the fractionation method seems to have sufficiently removed loosely associated proteins from nuclei therefore allowed us to enrich proteins and RNAs that are stably associated with chromatin/insoluble nuclear substructures.
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The isolated 'chromatin' fraction was then treated with RNase A to solubilize proteins that are anchored to chromatin through interaction with RNA or via association with such RBPs. Under the low salt condition used in this study, RNase A is less specific to single-stranded (ss) RNAs and is expected to digest also double-stranded (ds) RNA molecules to some extent. SDS-PAGE analysis and subsequent CBB staining revealed that a distinct set of proteins were released from the Table S1 .3). These findings assured that RBPs are preferentially released from chromatin/insoluble nuclear structures and we hereafter refer to the identified proteins simply as caRBPs.
As expected, GO Biological Function and KEGG pathway analysis of the identified caRBPs revealed that a large proportion of these proteins are related to mRNA biology including mRNA processing, surveillance, metabolism, transport and degradation ( Figure 2C , Table 2 , 3).
Besides this expected observation, some unexpected and interesting groups of proteins were identified.
In particular, proteins involved in the non-homologous end-joining (NHEJ) DNA repair pathway (DNA-PKcs, Ku80/XRCC5, Ku70/XRCC6, FEN1) and several metabolic enzymes, especially those involved in the tricarboxylic acid (TCA) cycle (ACLY, CS, IDH2) were markedly and consistently enriched in RNase A-solubilized fraction ( Figure 2C , Table 3 ). The presence of metabolic enzymes in chromatin-enriched fraction could be mere contamination by mitochondria and/or cytoplasmic materials. However, recent studies indicate that metabolic enzymes can indeed shuttle between mitochondria and nucleus and those in the nucleus may participate in transcriptional/chromatin regulation 16 . Also, it must be noted that the RNA-binding property of metabolic enzymes has long been known 17, 18 . Together with these circumstantial evidences, our finding supports the idea that a set of metabolic enzymes is associated with chromatin and raises the possibility that such interaction involves RNA.
In addition to the software-assisted analyses, manual extraction of proteins known to be a part of nuclear substructures or a transcription regulator showed enrichment for several transcription activators/regulators including ILF2/3 and PurA/B in RNase A-solubilized fraction (Table 4) .
Enrichment for a subset of paraspeckle proteins 19 was also observed. However, the observation needs to be interpreted with caution since many of the identified paraspeckle proteins are hnRNPs or those with additional functions besides paraspeckle formation. In addition, there was no clear enrichment for a particular class of paraspeckle proteins 19 (subclasses are indicated in Table 4 ).
While analyzing the datasets, we realized there were a considerable number of proteins that showed ≥ 2 fold enrichment over the control but failed to pass the statistical test Figure S2) . RNA-mediated interactions between these proteins and chromatin are likely to be biologically relevant and may worth further investigation. However, since we noticed that a fraction of the low confidence caRBPs seemed to correspond to proteins from contaminating organelles or cellular fractions. Consequently, we decided to focus on high confidence caRBPs (and hnRNP U from the low confidence candidates) for further analyses.
Verification of MS results by western blotting
Having obtained the list of RNase A-solubilized caRBPs, a handful of high confidence caRBPs (PurA, ILF3, DNA-PKcs, Ku80/XRCC5, Matrin-3) and hnRNP U were selected and the mass spectrometry results were confirmed by western blot (Figure 3) . For all the proteins tested, we could clearly detect increases in signals from the proteins released from chromatin upon RNase A treatment ( Figure 3) . Interestingly, the levels of PurA, hnRNP U and matrin-3 released from chromatin seemed to be dependent on the RNase A dose to a certain extent; more proteins were released at higher 
Different caRBPs appear to show different sensitivity to transcriptional inhibition
As revealed by recent analysis of global RNA-chromatin interaction, most of caRNAs appear to be nascent transcripts 5 . Thus, we wondered if association between RNA and caRBP is coupled with transcription. In order to address this point, HeLa S3 cells were treated with DRB, a reversible inhibitor of transcriptional elongation, and then subjected to cell fractionation and RNase A treatment ( Figure 4A ). RNase A-solubilized proteins were subsequently analyzed by western blot.
DRB treatment reduced the level of the elongation-associated form of RNA polymerase II (RNAPII Ser2P) 36 and to some extent overall RNAPII level in the nucleus ( Figure 4B ), indicating transcriptional elongation is sufficiently inhibited by the reagent. On the other hand, the nuclear protein levels of the caRBPs we tested were not greatly affected by the inhibitor treatment ( Figure 4B 
Conclusions
In this study we successfully narrowed down caRBPs to approximately 150 among over a thousand of known RBPs using a non-CLIP method. Since our experimental conditions and the cutoff values for analysis were set to identify highly reproducible caRPBs, the caRBPs listed here are likely to be the 'bona fide' caRBPs that participate in the most fundamental biological processes like transcription, DNA repair and mRNA processing, and metabolisms. In order to capture minor caRBPs, further optimization of experimental conditions and/or extra step to enrich such proteins from RNase A-solubilized fraction might be required. In addition, our analyses of RNase A-and RNase III-solubilized caRBPs suggest that use of different RNases may help to release and identify 'minor' or additional caRBPs.
Overall, this method is relatively simple, cheap and highly adaptable to any kinds of cells or organisms. By applying this method to different cell types or cells undergoing different stages of a physiological change, it may be possible to systematically identify functionally relevant, cell type-specific or stage-specific caRBPs. Moreover, our results from the DRB experiments suggest that combinatorial use of this methodology with various transcription/splicing inhibitor treatments may enable us to further characterize different types of caRNA-caRPB interactions. Last but not least, it is important to note that integration of proteomics data with genomics/transcriptomics data such as CLIP-seq results of caRBPs is necessary to generate a more comprehensive picture of caRNA-caRPB interactions. In conclusions, we anticipate future applications of this method in different biological as well as experimental contexts will give us deeper insights into caRNA-caRPB interactions.
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